LIMINATUS PHARMA INC-CL A (LIMN) Fundamental Analysis & Valuation

NASDAQ:LIMN • US53271X1081

Current stock price

0.1875 USD
-0.02 (-8.98%)
At close:
0.187 USD
0 (-0.27%)
After Hours:

This LIMN fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. LIMN Profitability Analysis

1.1 Basic Checks

  • LIMN had negative earnings in the past year.
  • LIMN had a negative operating cash flow in the past year.
  • LIMN had negative earnings in 4 of the past 5 years.
  • In the past 5 years LIMN always reported negative operating cash flow.
LIMN Yearly Net Income VS EBIT VS OCF VS FCFLIMN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 2025 0 -5M -10M

1.2 Ratios

  • LIMN's Return On Assets of -1990.44% is on the low side compared to the rest of the industry. LIMN is outperformed by 95.55% of its industry peers.
Industry RankSector Rank
ROA -1990.44%
ROE N/A
ROIC N/A
ROA(3y)-759.4%
ROA(5y)-463.88%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
LIMN Yearly ROA, ROE, ROICLIMN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 2025 0 -500 -1K -1.5K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for LIMN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LIMN Yearly Profit, Operating, Gross MarginsLIMN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 2025

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. LIMN Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, LIMN has more shares outstanding
  • LIMN has less shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, LIMN has an improved debt to assets ratio.
LIMN Yearly Shares OutstandingLIMN Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 2025 10M 20M 30M
LIMN Yearly Total Debt VS Total AssetsLIMN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M

2.2 Solvency

  • Based on the Altman-Z score of -147.66, we must say that LIMN is in the distress zone and has some risk of bankruptcy.
  • LIMN has a worse Altman-Z score (-147.66) than 94.97% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -147.66
ROIC/WACCN/A
WACCN/A
LIMN Yearly LT Debt VS Equity VS FCFLIMN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 2025 0 50M 100M 150M 200M 250M

2.3 Liquidity

  • LIMN has a Current Ratio of 0.05. This is a bad value and indicates that LIMN is not financially healthy enough and could expect problems in meeting its short term obligations.
  • LIMN has a Current ratio of 0.05. This is amonst the worse of the industry: LIMN underperforms 95.16% of its industry peers.
  • A Quick Ratio of 0.05 indicates that LIMN may have some problems paying its short term obligations.
  • LIMN has a worse Quick ratio (0.05) than 95.16% of its industry peers.
Industry RankSector Rank
Current Ratio 0.05
Quick Ratio 0.05
LIMN Yearly Current Assets VS Current LiabilitesLIMN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. LIMN Growth Analysis

3.1 Past

  • LIMN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -38.61%.
EPS 1Y (TTM)-38.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-295.24%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocksShow best growing peers

0

4. LIMN Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for LIMN. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LIMN Price Earnings VS Forward Price EarningsLIMN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LIMN Per share dataLIMN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.1 -0.2 -0.3 -0.4 -0.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. LIMN Dividend Analysis

5.1 Amount

  • No dividends for LIMN!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

LIMN Fundamentals: All Metrics, Ratios and Statistics

LIMINATUS PHARMA INC-CL A

NASDAQ:LIMN (4/10/2026, 8:00:02 PM)

After market: 0.187 0 (-0.27%)

0.1875

-0.02 (-8.98%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-31
Earnings (Next)06-01
Inst Owners0.71%
Inst Owner Change-0.01%
Ins OwnersN/A
Ins Owner Change0%
Market Cap8.41M
Revenue(TTM)N/A
Net Income(TTM)-10.21M
AnalystsN/A
Price TargetN/A
Short Float %4.51%
Short Ratio0.09
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.56
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.22
FCFYN/A
OCF(TTM)-0.22
OCFYN/A
SpS0
BVpS-0.22
TBVpS-0.22
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -1990.44%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-759.4%
ROA(5y)-463.88%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 727.78%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.05
Quick Ratio 0.05
Altman-Z -147.66
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-38.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-295.24%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-2.11%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-587.55%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-586.65%
OCF growth 3YN/A
OCF growth 5YN/A

LIMINATUS PHARMA INC-CL A / LIMN Fundamental Analysis FAQ

What is the fundamental rating for LIMN stock?

ChartMill assigns a fundamental rating of 0 / 10 to LIMN.


What is the valuation status of LIMINATUS PHARMA INC-CL A (LIMN) stock?

ChartMill assigns a valuation rating of 0 / 10 to LIMINATUS PHARMA INC-CL A (LIMN). This can be considered as Overvalued.


How profitable is LIMINATUS PHARMA INC-CL A (LIMN) stock?

LIMINATUS PHARMA INC-CL A (LIMN) has a profitability rating of 0 / 10.